Click here for slides on this topic


Niacin

Lipid-lowering agent; also called nicotinic acid.
The following content matched the glossary term: Niacin

AACE 2015 guidelines Cardiovascular Disease Management

Top

Summary of recommendations for managing cardiovascular disease (CVD), including dyslipidemia and hypertension, from the 2015 AACE diabetes guidelines 

Endocrine Society Guideline on Diabetes and Pregnancy - Glycemic Targets & Glucose Management

Top

Diabetes Management Guidelines Endocrine Society Guideline on Diabetes and Pregnancy   Source Blumer I, Hadar E, Hadden DR, et al. Diabetes and pregnancy an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2013 98(11) 4227 4249. Available here.Refer to

Clinical Insights April 2013

Top

The latest diabetes literature exploring diabetes guidelines, diabetes treatment, diabetes management, and diabetes prevention with commentary from diabetes experts.

Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy

Top

The AIM-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365(24):2255-2267. Residual cardiovascular (CV) risk persists among high-risk patients despite achievement of target LDL-C levels. In addition to elevated LDL-C, low HDL-C has been found in epidemiological studies to independently predict coronary heart disease (CHD) risk.

HPS2-THRIVE randomized placebo-controlled trial in 25,673 high-risk patients of ER niacin/laropiprant

Top

HPS2-THRIVE Collaborative Group. HPS2-THRIVE randomized placebo-controlled trial in 25,673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J. 2013;34(17):1279-1291. Residual risk for cardiovascular disease is seen among many high-risk patients despite LDL-C lowering with statins, and controlling blood pressure and diabetes. Niacin (nicotinic acid) is commonly prescribed as an add-on to statin therapy for incremental lowering of LDL-C, apoB, Lp(a), and triglycerides (TG); and incremental increasing of HDL-C and apoA1.

Triglycerides_Spanish

Top

 

Patient education handout exploring appropriate triglyceride levels and targets—in Spanish.

Triglycerides

Top

 

Patient education handout exploring appropriate triglyceride levels and targets.

Cholesterol_Spanish

Top

 

Patient education handout exploring appropriate cholesterol levels and targets—in Spanish.

Cholesterol

Top

 

Patient education handout exploring appropriate cholesterol levels and targets.

The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient

Top

Fruchart JC, Sacks FM, Hermans MP, et al, for the Residual Risk Reduction Initiative (R3I). The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient. Diab Vasc Dis Res. 2008;5(4):319-35. Despite current standards of care aimed at achieving targets for low-density lipoprotein (LDL) cholesterol, blood pressure and glycaemia, dyslipidaemic patients remain at high residual risk of vascular events.

1 2 Next 

Slide Library Results

Search Results for: Niacin Slides Found: 18
Effect of the Atkins Diet on Weight, Lipids, and Insulin
HPS2-THRIVE: Niacin and Vascular Risk
HPS2-THRIVE: Niacin +Laropiprant for Vascular Risk Reduction
HPS2-THRIVE: Baseline Characteristics
HPS2-THRIVE: LDL-Lowering Therapy Compliance
HPS2-THRIVE: Safety & Tolerability of Niacin ER + Laropiprant
HPS2-THRIVE: Liver & Muscle-Related Adverse Events
AIM-HIGH: Niacin + Statin Therapy for Cardiovascular Risk Reduction
AIM-HIGH: Design
AIM-HIGH: Baseline Characteristics
AIM-HIGH: Lipid Values at Baseline and 2 Years
AIM-HIGH: Rate of the Primary Endpoint
AIM-HIGH: Rate of Secondary Endpoints
ACC/AHA Cholesterol Guidelines 2013: Nonstatin Safety Recommendations: Niacin
IDF Type 2 Diabetes Guidelines CVD Risk Reduction Treatment | NDEI
Diabetes Pregnancy Guidelines Preconception CVD Dyslipidemia | NDEI
AACE 2015 Diabetes Guidelines Dyslipidemia Treatment PPT | NDEI
Pharmacotherapy for Dyslipidemia in Older Adults NLA Cholesterol Guidelines